LeukoScan technetium-99m-labeled antibody fragment that binds white blood cells data

IMMU reported on 28 patients in an ongoing Phase III trial, showing a sensitivity of 100 percent (true positive diagnosis), and a specificity (true negative rate) of 87 percent. The data were presente...